Valuation: Axogen, Inc.

Market Cap 2.18B 1.95B 1.81B 1.65B 3.11B 210B 3.13B 21.91B 8.52B 107B 8.2B 8.02B 345B P/E 2026 *
-92.5x
P/E 2027 * 454x
Enterprise Value 2.18B 1.95B 1.81B 1.65B 3.11B 210B 3.13B 21.91B 8.52B 107B 8.2B 8.02B 345B EV / Sales 2026 *
7.65x
EV / Sales 2027 * 5.95x
Free-Float
97.6%
Yield 2026 *
-
Yield 2027 * -
1 day-0.45%
1 week-14.22%
Current month-11.21%
1 month-22.91%
3 months-18.89%
6 months+8.07%
Current year+13.72%
1 week 36.79
Extreme 36.79
43.78
1 month 36.79
Extreme 36.79
48.1
Current year 27.54
Extreme 27.54
52.91
1 year 15.27
Extreme 15.2701
52.91
3 years 3.45
Extreme 3.45
52.91
5 years 3.45
Extreme 3.45
52.91
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 2024-08-08
Director of Finance/CFO 42 2025-05-11
Chief Operating Officer 65 2025-01-09
Director TitleAgeSince
Director/Board Member 65 2016-08-31
Director/Board Member 58 2019-05-14
Chairman 70 2024-08-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Sell

Director

-3,500 0.0065%
8/11/26 Exercice

Director

40,059 0.0745%
8/10/26 Exercice

Compliance Officer

202,500 0.3767%
Change 5-day change 1-year change 3-year change Capi.($)
-0.45%-14.22%+108.17%+675.42% 2.19B
+3.35%+0.26%+24.56%+34.69% 242B
+3.34%-1.46%+2.89%+2.38% 150B
+3.71%+0.32%-10.14%+40.03% 138B
-0.47%-3.46%-56.43%-17.75% 61.74B
+2.44%+1.09%+13.18%+22.39% 49.08B
-1.08%-0.90%-21.39%-22.66% 47.43B
+2.09%-0.87%+20.93%+53.39% 47.3B
+3.70%+0.99%-4.33%+41.39% 44.25B
+3.51%+1.52%+34.02%+64.37% 41.78B
Average +1.11%-3.63%+11.15%+89.37% 82.48B
Weighted average by Cap. +1.39%-3.01%+4.34%+26.38%

Financials

2026 *2027 *
Net sales 286M 254M 237M 216M 407M 27.49B 410M 2.86B 1.11B 14.02B 1.07B 1.05B 45.07B 367M 327M 305M 278M 524M 35.37B 527M 3.68B 1.43B 18.04B 1.38B 1.35B 57.99B
Net income -22.96M -20.47M -19.08M -17.37M -32.73M -2.21B -32.95M -230M -89.61M -1.13B -86.21M -84.34M -3.63B 3.1M 2.77M 2.58M 2.35M 4.42M 299M 4.45M 31.14M 12.11M 152M 11.65M 11.4M 490M
Net Debt - -
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, and NerveTape. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
26-10-05 US$37.22 -0.45% 2,099,486
26-10-02 US$37.39 -6.34% 3,098,410
26-10-01 US$39.92 -4.77% 1,600,587
26-09-30 US$41.92 -1.23% 1,089,097
26-09-29 US$42.44 -2.12% 1,407,685
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
37.22USD
Average target price
53.70USD
Spread / Average Target
+44.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXGN Stock